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Title: Surfactant therapy for bronchiolitis in critically ill infants.  
 
Background  
 
Viral bronchiolitis is a common cause of respiratory failure in children.  About 10 to 15% of previously 
healthy children are likely to be admitted to an intensive care unit (ICU) if they become hospitalised by 
bronchiolitis, and about half of these children will need mechanical ventilation. Children with pre-
existing conditions, such as congenital heart disease, chronic lung disease and children who are 
immunocompromised are at a much greater risk of developing bronchiolitis. 
 
The viruses that cause bronchiolitis cause the small airways in the child’s lungs to be obstructed, this 
causes them to cough and wheeze.  Bronchiolitis has no definitive treatment. Although many different 
therapies for bronchiolitis have been identified and studied, there isn’t currently enough evidence to 
support the use of any of them and children with bronchiolitis are often only given supportive care. 
 
Surfactant is a substance made up of proteins and lipids that is required for normal functioning of 
lungs. Severe bronchiolitis may also cause children to become deficient in surfactant. Surfactant has 
been suggested as a possible therapy for bronchiolitis as it is able to make the alveoli more stable 
and helps to improve mechanical properties of lungs. Therefore it has been suggested that 
administering surfactant into the lower airways might help children who develop severe bronchiolitis to 
recover from the disease more quickly. 
 
Objective/s (information similar to Review Question) 
To determine the efficacy of surfactant for the treatment of acute bronchiolitis in mechanically 
ventilated children when compared to placebo, no intervention or standard care 
 
Intervention/Methods (information similar to Study Characteristics) 
The authors searched for trials that looked at the outcomes of children who had been given surfactant 
after a diagnosis of acute viral bronchiolitis that required them to be intubated and mechanically 
ventilated. They included both children who had been previously healthy and those who were at high 
risk (i.e. those with congenital heart disease, chronic lung disease etc.) They included all randomised 
controlled studies, including both those that did and those that did not use a placebo control. 
 
The main outcomes they looked at were: mortality, duration of mechanical ventilation, duration of ICU 
stay and reported adverse effects. 
 
Results 
Three trials were included in the review, giving a total of 79 patients (39 received surfactant and 40 
were controls). One study used a placebo control. 
 
Outcomes: 
Mortality: No mortality was reported in any studies. 
 
Duration of mechanical ventilation 
All three studies showed that surfactant therapy reduced the length of time that a child needed to be 
mechanically ventilated, in one study this did not reach statistical significance. Combining the three 
studies showed no significant decrease in duration of mechanical ventilation, but a non-significant 
trend (2.6 days shorter).  
  
ICU Length of Stay 
All three studies showed that surfactant therapy reduced the length of stay in ICU, in one study this 
did not reach statistical significance. Combining the three studies showed a significant decrease in 
duration of ICU stay by 3.3 days.  
 
Adverse Effects 
No study in the review reported any adverse effect caused by taking surfactant. 
 
Conclusions 
Treating children with bronchiolitis who have been mechanically ventilated, with surfactant may be 
effective. These three small trials suggest that surfactant therapy for bronchiolitis might shorten the 
length of ICU stay, without having any serious adverse effects. However additional research is 
needed to clarify these findings. 
 
Implications for Practice 
Bronchiolitis can cause children to become seriously ill and no definite therapy is available. This 
review suggests that surfactant therapy might be an effective treatment for bronchiolitis in children 
who have needed to be mechanically ventilated. This could change the standard care for these sick 
children.  
 
However this review is based on three small studies and, although the results are promising, larger 
trials will need to be run to confirm this effect and answer questions about how the surfactant is best 
administered before guidelines will be changed. The three trials in the study adopted different 
approaches for administering the surfactant, one administered it after 12 hours of mechanical 
ventilation, another after 24 hours of mechanical ventilation and another gave two doses of surfactant. 
It is not clear how these differences in doses and timings might modify the effect of the surfactant 
therapy and these questions will need to be addressed before new guidelines are put into place. 
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